Abstract:You have accessJournal of UrologyCME1 Apr 2023MP09-10 PROSTATE IMAGING-REPORTING AND DATA SYSTEM VERSION 2 IN COMBINATION WITH CLINICAL PARAMETERS FOR PROSTATE CANCER DETECTION Lei Wang, Yi Luo, Tongzu Liu, Ming Deng, Hiroaki Wakimoto, and Xing Huang Lei WangLei Wang More articles by this author , Yi LuoYi Luo More articles by this author , Tongzu LiuTongzu Liu More articles by this author , Ming DengMing Deng More articles by this author , Hiroaki WakimotoHiroaki Wakimoto More articles by this author , and Xing HuangXing Huang More articles by this author View All Author Informationhttps://doi.org/10.1097/JU.0000000000003224.10AboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareFacebookLinked InTwitterEmail Abstract INTRODUCTION AND OBJECTIVE: The purpose of this study was to analyze the diagnostic performance of the Prostate Imaging Reporting and Data System version 2 (PI-RADS v2) in combination with clinical parameters in patients with suspected prostate cancer (PCa). METHODS: A total of 424 men with suspicion of PCa were retrospectively analyzed, who underwent multiparametric magnetic resonance imaging (mpMRI) evaluated with PI-RADS v2 prior to transperineal ultrasound guided systematic biopsy. Clinical parameters including age, prostate volume, prostate specific antigen (PSA), free/total PSA ratio (f/t PSA), PSA density (PSAD) and PI-RADS v2 score were investigated. Logistic regression analyses were performed to identify predictors of clinically significant PCa defined as a Gleason score of 3 + 4 or greater. The prediction performance was compared with PSA level, f/t PSA, PSAD, PI-RADS v2 alone, and PI-RADS v2 plus PSAD using receiver operating characteristics (ROCs). RESULTS: In total, 231 out of 424 cases (54.48%) were pathologically diagnosed as PCa. The percentage of clinically significant PCa was higher in patients with PI-RADS v2 score of 4 or greater compared to PI-RADS v2 score of less than 4 (90.86% vs. 55.88%, p < 0.001). Age, PSA level, f/t PSA, PSAD, and PI-RADS v2 were significant independent predictors of clinically significant PCa (Figure 1). The ROC area under the curve of PI-RADS v2 plus PSAD (0.952) was larger compared with PSA (0.845), f/t PSA (0.719), PSAD (0.920), and PI-RADS v2 alone (0.885) (Table 1, Figure 2). CONCLUSIONS: PI-RADS v2 in combination with PSAD may help detect clinically significant PCa and provide benefit in making the decision to biopsy men at suspicion of PCa. Source of Funding: None © 2023 by American Urological Association Education and Research, Inc.FiguresReferencesRelatedDetails Volume 209Issue Supplement 4April 2023Page: e108 Advertisement Copyright & Permissions© 2023 by American Urological Association Education and Research, Inc.MetricsAuthor Information Lei Wang More articles by this author Yi Luo More articles by this author Tongzu Liu More articles by this author Ming Deng More articles by this author Hiroaki Wakimoto More articles by this author Xing Huang More articles by this author Expand All Advertisement PDF downloadLoading ...

Prostate Imaging-Reporting and Data System Version 2 in Combination with Clinical Parameters for Prostate Cancer Detection: a Single Center Experience

Improving the Detection Rate of Prostate Cancer in the Gray Zone of PI-RADS V2 and Serum Tpsa by Using Prostate-Specific Antigen–age Volume

Optimizing Prostate Cancer Accumulating Model: Combined PI-RADS V2 with Prostate Specific Antigen and Its Derivative Data.

MP09-10 PROSTATE IMAGING-REPORTING AND DATA SYSTEM VERSION 2 IN COMBINATION WITH CLINICAL PARAMETERS FOR PROSTATE CANCER DETECTION

Combining prostate-specific antigen density with prostate imaging reporting and data system score version 2.1 to improve detection of clinically significant prostate cancer: A retrospective study

PI-RADS v2.1 and PSAD for the prediction of clinically significant prostate cancer among patients with PSA levels of 4–10 ng/ml

Combination of PI-RADS Score and PSAD Can Improve the Diagnostic Accuracy of Prostate Cancer and Reduce Unnecessary Prostate Biopsies

The Value of the Prostate Imaging Reporting and Data System Version 2 for the Diagnosis of Prostate Cancer

Diagnostic Value Analysis of PI-RADS v2.1 Combined with ADC Values in the Risk Stratification of Prostate Cancer Gleason Scores: A Retrospective Study

[Preliminary Applicability Evaluation of Prostate Imaging Reporting and Data System Version 2 Diagnostic Score in 3.0T Multi-Parameters Magnetic Resonance Imaging Combined with Prostate Specific Antigen Density for Prostate Cancer].

Performance of PI-RADS V2 Assessment Categories Assigned Prior to MR-US Fusion Biopsy in a New Fusion Biopsy Program.

The Efficiency of Multiparametric Magnetic Resonance Imaging (mpmri) Using PI-RADS Version 2 in the Diagnosis of Clinically Significant Prostate Cancer

Evaluation of the PI-RADS scoring system for detection of prostate cancer with targeted MRI-TRUS fusion-guided biopsy

Comparison of the diagnostic accuracy of clinically significant prostate cancer based on the PI-RADS: an interobserver study

The Diagnostic Value of PI-RADS V2.1 in Patients with a History of Transurethral Resection of the Prostate (TURP).

Combination of PI-RADS version 2.1 and amide proton transfer values for the detection of clinically significant prostate cancer

[The Clinical Decision-Making Value of Prostate Specific Antigen and Its Derived Indicators in Prostate Imaging Reporting and Data System Version 2 3 Lesions].

The Value of PI-RADS v2.1 Combined with PSAD Stratification in Predicting Peripheral Zone Clinically Significant Prostate Cancer in Patients with PSA 4-20 ng/mL

Combining Prostate Imaging Reporting and Data System, Histogram Analysis, and Prostate-Specific Antigen Density to Determine the Risk of Prostate Cancer in Patients With Prostate-Specific Antigen of 4 to 20 ng/mL.

A Calculator Based on Prostate Imaging Reporting and Data System Version 2 (PI-RADS V2) is a Promising Prostate Cancer Predictor

Assessment of Prostate Imaging Reporting and Data System Version 2.1 False-Positive Category 4 and 5 Lesions in Clinically Significant Prostate Cancer